BRAF Inhibition in Congenital Nevi and Neural Melanosis

Brent J. Doolan; Rebecca Levy; Tara McKeown; Anirban Das; Vijay Ramaswamy

doi:10.1001/jamadermatol.2026.1629

July 1, 2026JAMA Dermatology

BRAF Inhibition in Congenital Nevi and Neural Melanosis

View Full Paper

Ask AI

Bookmark

Share

Key Points

To report the effects of BRAF inhibition on neurologic and cutaneous symptoms in a patient with BRAF V600E–variant neurocutaneous melanosis.
BRAF inhibition was administered to the patient with neurocutaneous melanosis.
Neurologic and cutaneous changes were monitored over time.
Sustained neurologic improvement noted post-BRAF inhibition.
Significant cutaneous improvement observed, supporting the treatment's efficacy.

Implication

Case report shows sustained neurologic and cutaneous improvement following BRAF inhibition in a patient, suggesting effective treatment options.

Abstract

This case report describes sustained neurologic and cutaneous improvement following BRAF inhibition in a patient with BRAF V600E–variant neurocutaneous melanosis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Doolan et al. (2026) studied this question.

synapsesocial.com/papers/6a4752775c29257aa2579246 https://doi.org/10.1001/jamadermatol.2026.1629

View Full Paper

Ask AI

Bookmark

Share

BRAF Inhibition in Congenital Nevi and Neural Melanosis

Key Points

Implication

Abstract

Discussion

Cite This Study

BRAF Inhibition in Congenital Nevi and Neural Melanosis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading